financetom
Business
financetom
/
Business
/
IBM Unusual Options Activity For May 23
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
IBM Unusual Options Activity For May 23
May 23, 2024 1:25 PM

Financial giants have made a conspicuous bearish move on IBM ( IBM ). Our analysis of options history for IBM ( IBM ) revealed 8 unusual trades.

Delving into the details, we found 25% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $189,283, and 2 were calls, valued at $83,475.

Predicted Price Range

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $150.0 to $225.0 for IBM ( IBM ) during the past quarter.

Analyzing Volume & Open Interest

Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for IBM's ( IBM ) options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across IBM's ( IBM ) significant trades, within a strike price range of $150.0 to $225.0, over the past month.

IBM Call and Put Volume: 30-Day Overview

Biggest Options Spotted:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
IBM ( IBM ) CALL TRADE BEARISH 01/16/26 $37.0 $35.25 $35.25 $150.00 $52.8K 250 15
IBM ( IBM ) PUT TRADE BULLISH 05/31/24 $2.16 $2.1 $2.12 $172.50 $41.9K 451 327
IBM ( IBM ) PUT TRADE BEARISH 10/18/24 $12.05 $11.9 $12.05 $180.00 $33.7K 1.0K 43
IBM ( IBM ) PUT SWEEP NEUTRAL 01/17/25 $54.4 $51.35 $53.16 $225.00 $31.8K 20 6
IBM ( IBM ) CALL SWEEP BULLISH 01/17/25 $15.55 $15.3 $15.3 $170.00 $30.6K 3.3K 20

About IBM

IBM ( IBM ) looks to be a part of every aspect of an enterprise's IT needs. The company primarily sells software, IT services, consulting, and hardware. IBM ( IBM ) operates in 175 countries and employs approximately 350,000 people. The company has a robust roster of 80,000 business partners to service 5,200 clients—which includes 95% of all Fortune 500. While IBM ( IBM ) is a B2B company, IBM's ( IBM ) outward impact is substantial. For example, IBM ( IBM ) manages 90% of all credit card transactions globally and is responsible for 50% of all wireless connections in the world.

In light of the recent options history for IBM ( IBM ), it's now appropriate to focus on the company itself. We aim to explore its current performance.

Present Market Standing of IBM

Currently trading with a volume of 1,843,325, the IBM's ( IBM ) price is down by -1.68%, now at $170.78.

RSI readings suggest the stock is currently may be approaching overbought.

Anticipated earnings release is in 55 days.

Expert Opinions on IBM

5 market experts have recently issued ratings for this stock, with a consensus target price of $177.8.

Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on IBM ( IBM ) with a target price of $190.

Maintaining their stance, an analyst from BMO Capital continues to hold a Market Perform rating for IBM ( IBM ), targeting a price of $190.

An analyst from Exane BNP Paribas has revised its rating downward to Underperform, adjusting the price target to $145.

An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on IBM ( IBM ), which currently sits at a price target of $179.

Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for IBM ( IBM ), targeting a price of $185.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest IBM ( IBM ) options trades with real-time alerts from Benzinga Pro.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved